Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3120105 | 0.99 | S1PR1 (0.52) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL1449658 | 0.97 | S1PR1 (0.53) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| Hydrochloric Acid SCHEMBL3109957 | 0.96 | S1PR1 (0.52) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL777075 | 0.93 | S1PR1 (0.60) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| Hydrochloric Acid SCHEMBL3122033 | 0.92 | S1PR1 (0.59) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL5793202 | 0.91 | S1PR1 (0.57) | S1PR1S1PR3PRKXACVR1S1PR5 | |
| SCHEMBL3110012 | 0.89 | S1PR1 (0.45) | S1PR1S1PR3MAOB | |
| SCHEMBL3107537 | 0.88 | S1PR1 (0.44) | S1PR1S1PR3FFAR1FFAR4MAOB | |
| SCHEMBL3513167 | 0.88 | S1PR1 (0.48) | S1PR1S1PR3CYP4F2CYP4A11PRKX | |
| SCHEMBL3510909 | 0.88 | S1PR1 (0.48) | S1PR1S1PR3CYP4F2CYP4A11PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431275-B1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | KYORIN SEIYAKU KK (JP) | 2010-04-07 | — | — | EP | claimed |
| US-6963012-B2 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-11-08 | — | — | US | claimed |
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2004-12-02 | — | — | US | claimed |
| EP-1431275-A1 | DIARYL ETHER DERIVATIVE, ADDITION SALT THEREOF, AND IMMUNOSUPPRESSANT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2004-06-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242654-A1 | Diaryl ether derivative, addition salt thereof, and immunosuppressant | IL2, TSLP, HLA-DRB1 | S1PR1 927/4885S1PR3 776/4885CYP4F2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.